Last reviewed · How we verify
Treatment taken
This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells.
This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.
At a glance
| Generic name | Treatment taken |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, the drug allows the immune system to recognize and attack cancer cells more effectively, leading to an anti-tumor response. This mechanism of action is based on the principle of immune checkpoint inhibition, which has been shown to be effective in treating various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
- Melanoma
- Renal cell carcinoma
- Urothelial carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Abdominal pain
- Muscle weakness
- Arthralgia
Key clinical trials
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Disorders of the Acute Phase Response Following Trauma and Invasive Surgery (NA)
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- National Study on the Epidemiology and Effectiveness of Therapies in the Treatment of Scabies
- LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (PHASE2)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment taken CI brief — competitive landscape report
- Treatment taken updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI